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Abstract
Increasing evidence underlines the involvement of complement component C3 in the establishment 
of acquired immunity which appears to play a complex role and to act at different levels. As antigen 
proteolysis by antigen presenting cells is a key event in the control of antigen presentation efficiency, 
and consequently in the quality of the immune response, we investigated whether C3 could modulate 
this step. Our results demonstrate for the first time that C3 can interfere with antigen proteolysis: i) 
proteolysis of tetanus toxin (TT) by the lysosomal fraction from a human monocytic cell line (U937) 
is impaired in the presence of C3, ii) this effect is C3-specific and involves the C3c fragment of the 
protein, iii) C3c is effective even after disulfide disruption, but none of its three constitutive peptides 
is individually accountable for this inhibitory effect, iv) the target protease(s) exhibit(s) a serine-
protease activity. The physiological relevance of our results is demonstrated by experiments showing 
a subcellular colocalisation of TT and C3 after their uptake by U937 and the reduction of TT 
proteolysis once internalised together with C3. 
These results highlight a novel role for C3 that broadens its capacity to modulate acquired immune 
response. 
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1. Introduction 
 
                                                          
The involvement of the complement system, a key component of innate immunity, in the 
establishment of the adaptative immune response is now well-documented (reviewed in references 
(Carroll, 2004; Walport, 2001)). Among the components of the complement cascade, C3 plays a 
unique role, due to its different characteristics: not only is it the most abundant complement protein in 
serum, but it is also the meeting point of the three activation pathways of the complement cascade. 
Moreover, C3 belongs to the α2-macroglobulin (α2-M) family that contains an intrachain thioester 
bond (Dodds and Law, 1988). The breakdown of this bond upon activation of C3 to C3b results in a 
transient capacity for the molecule to form a covalent bond with nucleophilic acceptors such as amino 
Abbreviations : α2-M, alpha2-macroglobulin; Ag, antigen; DFP, di-isopropyl fluorophosphate; LF, 
lysosomal fraction; SBTI, soybean trypsin inhibitor; TT, tetanus toxin. 
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or hydroxyl groups (Law et al., 1979; Sim et al., 1981). Finally, C3b can undergo successive rounds 
of cleavage leading to different fragments (iC3b, C3dg), each of them being able to interact 
specifically with receptors expressed by most immune cells (Villiers and Villiers, 2003; Villiers et al., 
2004). These characteristics confer a variety of different properties to C3 and its fragments, including 
acting as bifunctional ligands between antigens (Ag) and cells (Villiers et al., 2003; Villiers et al., 
1996; Weiss et al., 1989), as signalling effectors (Cherukuri et al., 2001; Fearon and Carter, 1995; 
Wagner et al., 2006), or as anaphylatoxins (Hawlisch et al., 2004; Schulman et al., 1988; Takafuji et 
al., 1994). The role of C3 in acquired immune response modulation has first been demonstrated “in 
vivo”, using complement-depleted or -deficient animals (Bottger et al., 1986; Ochs et al., 1983; 
Pepys, 1974). Increasing evidence from “in vivo” as well as “in vitro” experiments has raised since, 
revealing the complexity of this modulatory effect which operates at different levels, including 
cytokine release, T cell proliferation, regulatory T cell development and B cell 
activation/differentiation (reviewed in references (Carroll, 2004; Morgan et al., 2005; Wagner and 
Hansch, 2006)). The mechanisms involved are not yet fully understood and are still under 
investigation.  
Previous work using C3b-TT complexes demonstrated the influence of C3b on Ag presentation at 
the cellular level. Ag recognition by T lymphocytes requires Ag processing by antigen presenting cell 
(APC), which involves limited proteolysis, loading of the antigenic peptides onto MHC-II molecules 
and presentation of the MHC-II – peptide complexes to the cell surface. We demonstrated previously 
that C3b fixation on TT results in increased Ag uptake by APC (Rey-Millet et al., 1994; Villiers et al., 
1996), improved antigenic peptide binding on MHC class II molecules (Serra et al., 1997), modified 
intracellular trafficking (Perrin-Cocon et al., 2004; Rey-Millet et al., 1994) and delayed Ag 
proteolysis in subcellular compartments (Jacquier-Sarlin et al., 1995). To gain new insight into this 
last point, we assessed here whether C3b per se, affects the activity of lysosomal proteases involved 
in Ag processing, using TT as model Ag. Experiments were performed with monocytic cells (U937) 
as i) they have higher protease content than B cells or dendritic cells (Delamarre et al., 2005) and ii) 
they are known to secrete larger amount of C3 at sites of inflammation than other APC (Einstein et 
al., 1977). Our results constitute the first evidence that C3b can indeed inhibit lysosomal proteases. 
This inhibitory activity is specific of C3b and is supported by the C3c fragment. The presence of the 
three C3c polypeptides is required, although their disulfide linkage is not imperative. The use of 
known protease inhibitors suggests that the target-protease(s) of C3b belong(s) to the serine-protease 
family. Finally, experiments using living cells demonstrate the physiological relevance of these 
results. 
 
2. Materials and methods 
 
2.1. Proteins 
 
 Purified TT was generously supplied by Dr J.R. Cartier (Institut Mérieux, France) 
and was further purified as described previously (Villiers et al., 1991). Trypsin (L-
tosylphenylalanyl chloromethane-treated), soybean trypsin inhibitor (SBTI), ovalbumin, 
BSA, and hemoglobin were from Sigma Aldrich Co., St Louis, Mo., USA. Elastase was from 
Roche Diagnostic, Meylan, France. α2-M was a kind gift from Dr J.-J. Feige (IRTSV/APV, 
Grenoble, France). Immunoglobulin G2a was produced by a hybridoma derived from 
BALB/c. 
 
2.2. Purification of C3 and its fragments 
 
 C3 was purified from outdated human citrated plasma obtained from the 
Etablissement Français du Sang (Grenoble, France) according to (Al Salihi et al., 1982). C3b 
was prepared by incubating purified C3 with 0.1% (w/w) trypsin at 23°C for 1 h and the 
reaction was stopped by adding 0.2% (w/w) SBTI and incubating at 37°C for 15 min. C3c 
and C3de were obtained by incubating C3 with elastase (100/5, w/w) in PBS during 18 h at 
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37°C. The two fragments were further purified using a Sephadex G-100 superfine (2.6 x 90) 
column equilibrated in 150 mM NaCl, 20 mM Tris-HCl, pH 7.2, at a flow rate of 8 ml/h. The 
three polypeptides constituting C3c (α1, α2 and β) were obtained after reduction of the 
molecule (1h at 37°C in the presence of 50 mM dithiothreitol) followed by alkylation (30min 
at 37°C in the presence of 137 mM iodoacetamide), and purification by reverse phase-HPLC 
using a Vydac C4 column (Interchim, Montluçon, France). The polypeptides were acidified 
using trifluoroacetic acid 0.1% (v/v), loaded onto the column at 0.25ml/min and eluted using 
a linear acetonitril gradient (0-80%, v/v). Absorbance was monitored at 215 nm. The 
concentration of purified proteins was estimated from absorbance at 280 nm, using E1%, 1 
cm = 11.5 for TT (Villiers et al., 1993), 9.7 for C3 and C3b (Tack and Prahl, 1976), 10.0 for 
C3c, 13.34 for C3de and for the fragments (α1: 4.57, α2: 11.23, and β: 7.97), values were 
calculated using the ExPASy facilities. 
 
2.3. Protein labelling 
 
2.3.1 Radioactivity: Proteins were labelled with Na 125I using the iodogen method 
(Salacinski et al., 1981). 125I (3.7GBq/ml) was from GE-Healthcare (France) and the Iodogen 
iodination reagent was from Pierce Chemical Co. (Interchim, Montluçon, France). 
Free iodine was eliminated by filtration through a Sephadex G50-fine column (GE-
Healthcare, France). Specific radioactivity was 170 Bq/µg. 
2.3.2. Fluorescence: Proteins were labelled with Cy2 (TT) and Cy3 (C3) (GE-
Healthcare, France) as recommended by the manufacturer. 
 
2.4. Cells and culture condition 
 
 U937 cells (Sundström and Nilsson, 1976) were obtained from the American Type 
Culture Collection (Manassas, VA, USA) and maintained in culture at 0.5 x 106 cells/ml in 
RPMI-1640 (Invitrogen, France), supplemented with 2 mM L-glutamine and 10% heat-
inactivated (56°C, 30min) foetal calf serum. Cultures were routinely passaged every 3 days 
and cells were used 24 h after the last passage. 
 
2.5. Subcellular fractionation 
 
Cells (70 x 106 cells/ml in 250 mM sucrose, 1 mM EDTA, 1 mM hepes, pH 7.2) were 
disrupted and fractionated on a Percoll gradient as previously described (Villiers et al., 1996). 
LF was characterized as previously described (Perrin-Cocon et al., 2004) and stored at -80°C 
until use. 
 
2.6. Analysis of TT proteolysis 
 
2.6.1. by lysosomal fraction: 125I-TT (5 µg) was incubated in 50 mM Na acetate (50 
µl) for 18 h at 37°C, in the presence of LF (equivalent to 2.5 x 106 cells) and of different 
proteins (5 µg). The mixture was analyzed on SDS-PAGE (10-15% acrylamide) in non 
reducing conditions and the radioactivity associated with the protein bands was quantified 
using a Phosphorimager (GE-Healthcare, France). TT proteolysis was assumed to be the 
reduction in the 150 kDa band (= intact TT) radioactivity compared to the total radioactivity 
present on the gel. 
2.6.2. by U937 cells: 10 x 106 cells were incubated at 37°C for different times in the 
presence of 125I-TT (0.1mg/ml) alone or with C3b (0.1mg/ml). Then, cells were washed three 
times in PBS and disrupted using a “cell-disrupter” (1 shot-0.75 kW model, Constant systems 
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Ltd., Warwick, U.K.) with a pressure of 350 bar. Two successive centrifugations were 
performed first to remove intact cells and membranes (3min at 1,500g) and then to 
concentrate the subcellular compartments (10min at 10,000g). The pellet was resuspended in 
50µl of denaturing buffer (8M urea, 2% SDS, 0.2M tris, pH 8.0) and analysed on SDS-PAGE 
(7.5% acrylamide). 
 
2.7. Confocal microscopy 
 
Cells in 100 µl culture medium (107/ml) were incubated in the presence of fluorescent 
TT and C3b (0.1 mg/ml each) at 37°C for 2h. Cells were washed three times in PBS and 
allowed to adhere on poly-L-lysine-coated lamellas for 40 min at room temperature. Lamellas 
were washed three times in PBS and cells were fixed with paraformaldehyde 3% (w/v) in 
PBS, 10min at room temperature. Samples were mounted in Dako fluorescent mounting 
medium (Beckman Coulter, Roissy CDG, France), sealed, and stored at 4 °C in the dark. 
Fixed cells were imaged at room temperature using the inverted confocal and two-photon 
laser-scanning microscope (LSM 510 NLO, Carl Zeiss) equipped with a 40×/1.3 Plan-
Neofluar oil immersion objective. The pinhole adjustment to 1 Airy unit resulted in less than 
0.7 μm optical slice at 488 nm excitation wavelength. The image plane was chosen to be near 
the equator of the cell body and nucleus. No significant photobleaching was induced during 
image acquisition in either detection channel. 
 
3. Results 
 
3.1. Inhibitory effect of C3 upon tetanus toxin (TT) proteolysis by lysosomal fraction (LF) 
 
In order to assess whether C3 could affect some proteolytic processes, 125I-TT proteolysis by 
the LF of U937 cells was analyzed in the presence or absence of C3, as described in the Materials and 
Methods section. As shown in Fig.1, TT is present as two close bands (Mr = 150,000 and 140,000) on 
SDS-PAGE under non-reducing conditions (lane 1) and is partially proteolyzed by LF (lane 2), as 
indicated by the appearance of three new major bands (Mr = 100,000, 48,000 and 46,000) together 
with small fragments (Mr < 15,000) migrating with the dye front, and the parallel decrease in band 
intensity corresponding to intact TT. An additional, fainter, band featuring an apparent Mr = 120,000 
can also be detected. When C3 is added to the mixture prior to incubation of TT with LF, a similar 
electrophoretical pattern is observed, although the amount of non-proteolyzed TT remains higher than 
in the absence of C3 (lane 3): C3 does therefore not modify the proteolytic fragments generated by 
LF, but rather at least partially inhibits its proteolytic activity. 
The inhibitory effect of C3 on TT proteolysis by LF was confirmed by a kinetic analysis: As shown in 
Fig.2, in these conditions, only 15% of input TT is proteolyzed after a 24 h incubation in the presence 
of C3 against 45% in its absence. 
 
3.2. Specificity of the C3 inhibitory effect 
 
To assess the specificity of the observed C3 inhibitory effect, 125I-TT was incubated with LF 
in the presence of various unlabelled proteins (TT=150kDa, C3=185kDa, ovalbumine (Ova)=43kDa, 
BSA=67kDa, hemoglobine (Hem)=68kDa, IgG2a=150kDa, α2-M=4x180kDa) and its proteolysis was 
quantified after SDS-PAGE. An assay including only 125I-TT and LF was used as reference (100% 
proteolysis). As shown in Fig.3A, proteolysis is substantially inhibited only in the presence of C3; the 
other proteins tested, by contrast, only slightly decrease TT proteolysis by LF. Surprisingly, this is 
also the case of α2-M, which belongs to the same family as C3 (thioester-containing proteins). The 
observed inhibitory effect is therefore specific to C3. The mild proteolysis inhibitory effect featured 
by all the tested proteins with the exception of C3 is probably due to the fact that these molecules are 
all potential substrates for proteases, and therefore potential 125I-TT competitors for LF proteolysis. 
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Therefore, in the following experiments, the reference assays will always include unlabelled TT (5µg) 
in order to eliminate the slight inhibition due to this phenomenon and to take in account only the 
effect due to C3. 
 
3.3. Identification of the C3 fragment involved in proteolysis inhibition 
 
Under physiological conditions, C3 undergoes successive proteolytic cleavages leading to 
various fragments, namely C3b, which is subsequently cleaved into iC3b (Mr = 175,000 and 173 000 
respectively), then into C3c (Mr = 135,000) and C3de (Mr = 40,000) (Villiers and Villiers, 2003). In 
order to identify the C3 fragment involved in proteolysis inhibition, 125I-TT was incubated with LF in 
the presence of each of the different C3 fragments and analyzed using SDS-PAGE. As shown in 
Fig.3B, TT degradation by lysosomal proteases is impaired in the presence of C3, C3b and C3c 
fragments (40-50% inhibition), but this effect is less significant  in the presence of C3de (80%). 
Therefore, the observed proteolysis inhibitory effect of C3 is related to the C3c fragment. As 
evidenced using SDS-PAGE (Fig.4A), the C3c fragment (apparent Mr = 135,000 in non reducing 
conditions) is made of three disulfide-linked polypeptides: the C3 β chain (Mr = 75,000) and the two 
α chain-derived polypeptides (α1, Mr = 40,000 and α2, Mr = 27,000). We wondered whether the C3c 
inhibitory effect required the integrity of the molecule. To that aim, C3c was further incubated with 
trypsin (trypsin/C3c = 1/100, w/w, 2h at 37°C): further cleavage of β, α1 and α2 was obtained, leading 
to three other polypeptides (β*, Mr = 58,000, α1*, Mr = 34,000 and α2*, Mr = 23,000). 125I-TT 
proteolysis by LF in the presence or absence of trypsin-treated C3c was no longer inhibited by C3c 
after trypsin digestion (Fig.4B), testifying to the need for the integrity of this fragment. As i) 
proteolytic activities are present in LF and ii) proteolyzed C3c does not retain any inhibitory effect, 
we investigated whether the C3 fragment is degraded upon incubation in the presence of LF. C3c is 
fairly resistant to proteolysis by lysosomal proteases (12.5% degradation upon a 18h incubation, data 
not shown), which is consistent with its inhibiting activity upon TT degradation by LF. 
 
3.4. Identification of the C3c domains involved in proteolysis inhibition 
 
To localize the proteolysis inhibitory activity within C3c, the protein was reduced and we 
purified its three polypeptide constituents (β, α1 and α2) using HPLC (Fig.5A). Each polypeptide was 
then tested individually for its capacity to inhibit the proteolytic activity of LF. As shown in Fig.5B, 
whereas reduction of C3c by itself does not abolish its inhibitory effect, neither fragment is alone 
sufficient to impair TT proteolysis; in other words, the inhibitory effect of C3c, although independent 
of disulfide bridge integrity, cannot be attributable to only one of its three constitutive peptides.  
 
3.5. Characterisation of the protease family inhibited by C3 
 
The protease(s) involved in TT proteolysis by LF was (were) characterized by incubating 
TT and LF in the presence of different inhibitors: DFP, EDTA, pepstatin A, iodoacetic acid . As 
illustrated in Fig.6, proteolysis of TT is mainly due to DFP-sensitive protease(s) rather than metallo-, 
acid- or thiol-proteases, as it is affected only slightly by EDTA, pepstatin A or iodoacetic acid (7-15% 
inhibition), whereas DFP strongly decreases TT proteolysis (58%), to an extent similar to C3 (40%). 
Moreover, the TT fragments which accumulate upon TT + LF incubation in the presence of DFP are 
similar to those observed in the presence of C3 whereas the presence of the other inhibitors leads to a 
different accumulation of fragments (data not shown). These results suggest that the target-protease(s) 
for C3 belong(s) to the serine-protease family. 
 
3.6. Colocalisation of TT and C3 upon cellular internalisation 
 
To determine if our observations made in a cell free system are physiologically relevant, we 
have first analysed the localisation of TT and C3b after their uptake by living cells (C3b was used 
instead of C3 in order to allow C3b internalisation via complement receptors).  To do so, U937 were 
allowed to internalise Cy2- TT and Cy3-C3b at 37°C before being examined by confocal microscopy. 
 5
As it can be seen in Fig.7, some intracellular compartments contain only C3b. On the contrary and 
although TT is less efficiently internalised, it always colocalise with C3b as there is always an 
overlapping of green with red signals (yellow in merged images). One observes this phenomenon 
whatever the duration of the incubation, from 20min to 2h. 
 
3.7. Inhibitory effect of C3 upon TT proteolysis in U937 
 
As we demonstrated the inhibitory activity of C3 upon TT proteolysis by LF and the 
colocalisation of these two proteins after U937 internalisation, we wondered whether C3 could also 
influence TT proteolysis in living cells. After allowing U937 to internalise 125I-TT alone or with C3b 
for different times at 37°C, we analysed TT proteolysis on SDS-PAGE. The quantification of the peak 
corresponding to intact TT indicates that C3b interferes with intracellular proteolytic activities in 
living cells as the amount of unproteolysed TT is doubled in presence of C3b, at least during the first 
40min after internalisation (Fig. 8). 
 
4. Discussion 
 
The influence of complement component C3 on Ag presentation has been highlighted since several 
years. Indeed, it has been demonstrated that C3b modulates Ag processing and presentation by 
different APC upon covalent binding to Ag (Jacquier-Sarlin et al., 1995; Rey-Millet et al., 1994). 
Using macrophages from C3-deficient mice, Zhou et al. (Zhou et al., 2006) have presented evidence 
that C3 also modulates the potency of APC to stimulate the T-cell response, suggesting a potential 
effect of free C3 on immune reponse. As peptide generation through Ag degradation is a key event for 
both Ag presentation and T cell stimulation, we wondered whether free C3 could modulate Ag 
proteolysis in APC. To be able to correlate our present work with previous ones, we used the same Ag 
model (TT). 
Our results demonstrate that proteolysis of TT by the LF from a human monocytic cell line (U937) 
was impaired by C3. This effect was quite specific of C3, as α2-M, another protease inhibitor 
belonging to the same intramolecular thioester bond-containing family (Armstrong and Quigley, 
1999), did not affect TT proteolysis. The specificity of C3 inhibitory effect is strengthened by the fact 
that all other proteins tested were without effect although they are added at same or greater number of 
molecules compared to C3, depending on their MW.  We further identified C3c as being responsible 
for inhibiting TT proteolysis by LF. It is noteworthy that C3c retained its proteolysis inhibitory 
activity even after disulfide disruption, although neither of its three constitutive peptides could 
individually be accountable for it. This observation could be related to the intrinsic structure of C3c: 
C3c consists of several domains, one of which is formed by parts of both the β- and α-chains (Janssen 
et al., 2005). This β/α intertwined domain, which is not stabilized by a disulfide bridge and is thereby 
preserved even after reduction of the molecule, which is confirmed by the impossibility of separating 
the three polypeptides by gel filtration at neutral pH (data not shown). Thus, it is likely that this β/α 
intertwined domain could be involved in the observed inhibitory effect of C3c.  
Previous studies have illustrated the role of C3 in Ag presentation (Jacquier-Sarlin et al., 1995; 
Rey-Millet et al., 1994; Santoro et al., 1994), and particularly in Ag degradation: indeed, Jacquier-
Sarlin et al. reported limited TT proteolysis by B cells in the presence of C3b (Jacquier-Sarlin et al., 
1995). Furthermore, antigenic peptides production and loading on MHC II molecules are modified 
upon covalent binding of C3b to the Ag (Cretin et al., 2007; Serra et al., 1997). It has been shown that 
the TT-C3b interaction is fairly stable in endosomes, whereas it is gradually disrupted in lysosomes 
(Rey-Millet et al., 1994). Moreover, LF contains proteolytic activities leading to the generation of 
C3c-like fragments (Rey-Millet et al., 1993). These results, together with our present work, enable us 
to suggest a mechanism by which C3b binding to Ag may modulate Ag presentation: after their 
uptake by APC, Ag-C3b complexes are delivered to lysosomes, where C3c fragments are generated 
upon lysosomal proteolytic activities. These fragments then interfere with the lysosomal proteases and 
at least partially inhibit their activity. 
This hypothesis is strengthened by our experiments using living cells. First, analysis by confocal 
microscopy of U937 having internalised TT and C3 showed that C3 is always found in subcellular 
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compartments containing TT, which makes possible their interaction. The great efficiency of C3 
uptake compared to TT is probably due to the presence of C3 receptors at the surface of  U937 
(CD11b, CD11c, (Lopez-Rodriguez and Corbi, 1997)). Thus, whereas TT is internalised only via 
pinocytosis and phagocytosis, C3 could enter the cells using both receptor –independent 
(colocalisation with TT) and receptor -dependent pathway which may lead in this case to a different 
subcellular localisation (C3 alone) as shown previously on B cells (Perrin-Cocon et al., 2004). 
Second, the analysis of the intracellular proteolysis of TT by living APC such as U937 demonstrates 
that C3 is able to exert its inhibitory effect in physiological conditions. This effect decreases with 
time, but persists at least during the first hour after internalisation. It has been demonstrated that 
modulation of Ag proteolysis may interferes with Ag presentation, either by increasing or by 
decreasing production of antigenic peptides suitable for MHC binding (Delamarre et al., 2006; Polla 
et al., 2007). 
The proteases involved in Ag degradation and the mechanisms that control their activities are not 
yet fully understood and differ according to the Ag and the cells involved (Burster et al., 2005). 
Cathepsins are often associated with Ag proteolysis (Hewitt et al., 1997; Hsieh et al., 2002; Ruckrich 
et al., 2006; Shi et al., 1999), but other proteases such as asparagine endopeptidase (AEP) also play an 
important role (Manoury et al., 1998). In our hands, C3c inhibited TT proteolysis in a way similar to 
DFP, indicating that the target protease(s) belongs to the serine-protease family; this conclusion is 
strengthened by the fact that all other protease inhibitors tested had less effect on TT proteolysis. A 
previous study by Rey-Millet et al. (Rey-Millet et al., 1993) pointed out the presence of a serine-
protease activity within LF, but its involvement in Ag processing had not been established. Most 
attempts to identify the proteases accounting for intracellular Ag proteolysis are usually indirect, 
consisting in the analysis of Ag presentation to T cells in the presence of different inhibitors. Ag 
degradation has either a creative or a destructive effect, mainly depending on MHC restriction (Puri 
and Factorovich, 1988; Takahashi et al., 1989). Nevertheless, inhibition of Ag degradation is often 
related to increased Ag presentation, as demonstrated using protease inhibitors (Vidard et al., 1991), 
antigen resistant to degradation (Delamarre et al., 2006) or modulation of intravacuolar pH (Savina et 
al., 2006). Indeed, reduced intracellular proteolysis avoids the destruction of T cell epitopes, favoring 
the production of peptide-MHC classs II complexes. This is particularly important in cells such as 
macrophages which possess elevated degradation capacity due to their high protease content. Here, 
we provide direct evidence for the control of Ag proteolysis by C3c, which could be related to the 
previously described C3-mediated enhancement of Ag presentation and, more generally, of the 
establishment of a specific immune response. C3 is therefore directly involved in Ag degradation by 
APC through at least two distinct mechanisms: i) C3b modulates Ag trafficking within the APC 
(Perrin-Cocon et al., 2004) thereby potentially affecting Ag processing through modified protease 
activities located within the intracellular compartments, and ii) C3 directly inhibits Ag proteolysis by 
lysosomal proteases, as illustrated by our results. The C3 present in APC could be of extracellular 
origin, via C3b binding to exogenous Ag, as well as of intracellular origin, since C3 is synthesized by 
various APC such as dendritic cells (Peng et al., 2006) or macrophages (Fischer et al., 1998). Whether 
endogenous C3 could influence Ag proteolysis in the same way as exogenous C3 or not remains to be 
established. Nevertheless, the relevance of the role of C3 in Ag presentation “in vivo” has been 
highlighted by Zhou et al.(Zhou et al., 2006), who demonstrated that stimulation of alloreactive T 
cells is impaired in C3-deficient mice. 
The capacity of C3c to control lysosomal degradation could provide an explanation as to why 
induction of an increased Ab response in mice requires injection of three C3d molecules bound to Ag 
(Dempsey et al., 1996) versus a single molecule of C3b (Villiers et al., 1999). Indeed, only C3b 
allows local production of C3c which could control Ag proteolysis favouring Ag presentation, while 
Ag uptake can be ensured by both C3b and C3d. 
In conclusion, our results, by revealing a novel role for C3, supplement the integrative view on the 
modulatory role of C3 in acquired immune response, and especially on Ag processing: C3 acts at 
different levels such as Ag uptake (Villiers et al., 1996), intracellular Ag trafficking and targeting 
(Perrin-Cocon et al., 2004), proteolytic machinery of Ag processing (these results), Ag peptide editing 
(Cretin et al., 2007) and loading on MHC II molecules (Serra et al., 1997), all of these increasing Ag 
presentation efficiency (Jacquier-Sarlin et al., 1995) and thus the quality of the acquired immune 
response (Dempsey et al., 1996; Villiers et al., 1999). 
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Figure Captions 
 
Fig. 1. TT proteolysis by LF. 125I-TT (5 µg) was incubated for 18 h at 37°C in the presence or absence 
of LF from U937 cells (2.5 x 106 cells) and of C3 (5 µg). The mixture was analyzed by SDS-PAGE 
under non reducing conditions (A). The radioactivity associated with the protein bands was quantified 
using a phosphorimager (B).  
 
Fig. 2. Kinetic analysis of TT proteolysis by LF in the presence or absence of C3. 125I-TT (5 µg) was 
incubated at 37°C for different times in the presence of LF from U937 cells (2.5 x 106 cells) and of C3 
(5 µg). TT proteolysis was analyzed by SDS-PAGE and quantified as described in Materials and 
Methods. Results are given as means ±SD from at least three separate experiments. 
 
Fig. 3. Specificity of the C3 inhibitory effect and identification of the C3 fragments involved. 125I-TT 
(5 µg) was incubated for 18 h at 37°C in the presence of LF from U937 cells (2.5 x 106 cells) and of 5 
µg of various proteins: A) TT, C3, ovalbumine (Ova), BSA, hemoglobine (Hem), IgG2a, α2-M and B) 
C3 fragments. 125I-TT proteolysis was analyzed by SDS-PAGE and quantified as described in 
Materials and Methods. (A) 100% proteolysis was determined using an assay including only 125I-TT + 
LF (Ctl). (B) 100% proteolysis was determined using an assay including 125I-TT + LF and unlabelled 
TT (Ctl). Results are given as means ±SD from at least three separate experiments. 
 
Fig. 4. Loss of the C3 inhibitory effect after C3c cleavage. (A) SDS-PAGE analysis of C3c (5 µg) in 
non reducing (NR) and reducing (R) conditions before and after cleavage by trypsin (see Materials and 
Methods). (B) TT proteolysis by LF in the presence of intact or trypsin-proteolyzed C3c. 125I-TT (5 
µg) was incubated for 18 h at 37°C in the presence of LF from U937 cells (2.5 x 106 cells) and C3c (5 
µg) treated or not by trypsin. TT proteolysis was analyzed by SDS-PAGE and quantified as described 
in Materials and Methods. 100% proteolysis was determined using an assay including 125I-TT + LF 
and unlabelled TT. Results are given as means ±SD from at least three separate experiments. 
 
Fig. 5. Identification of C3c domains involved in proteolysis inhibition. After reduction and alkylation 
of C3c, the different polypeptides were purified by reverse phase-HPLC on a Vydac C4 column (see 
Materials and Methods). (A) Elution profile. (B) TT proteolysis by LF in the presence of reduced or 
non reduced C3c or each of its constitutive peptides. 125I-TT (5 µg) was incubated for 18 h at 37°C in 
the presence of LF from U937 cells (2.5 x 106 cells) and C3c or its peptides (5 µg). TT proteolysis was 
analyzed by SDS-PAGE and quantified as described in Materials and Methods. 100% proteolysis was 
determined using an assay including 125I-TT + LF and unlabelled TT (Ctl). Results are given as means 
±SD from at least three separate experiments. 
 
Fig. 6. Characterization of the lysosomal protease family involved in TT proteolysis. 125I-TT (5 µg) 
was incubated for 18 h at 37°C in the presence of LF from U937 cells (2.5 x 106 cells) and C3 (5 µg) 
or different protease inhibitors (DFP, EDTA, iodoacetic acid (5mM) or pepstatin A (1.5µM)). TT 
proteolysis was analyzed by SDS-PAGE and quantified as described in Materials and Methods. 100% 
proteolysis was determined using an assay including 125I-TT + LF and unlabelled TT (Ctl). Results are 
given as means ±SD from at least three separate experiments. 
 
Fig. 7. Localisation of internalised TT and C3b by confocal microscopy. U937 were incubated at 37°C 
for 2h in the presence of Cy3-C3b and Cy2-TT. Merged images of red (C3b) and green (TT) 
fluorescence are shown. 
 
Fig. 8. TT proteolysis by U937 in the presence or absence of C3b. 125I-TT (100µg) was internalised by 
U937 (10 x 106 cells) at 37°C for the indicated times in the presence or not of C3b (100µg). After cell 
disruption, samples were treated as described in Materials and Methods and analysed by SDS-PAGE. 
Residual intact TT was quantified after 20, 40 and 60min incubation as described in Materials and 
Methods. Results are given as means ±SD from at least three separate experiments. 
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